Read + Share
Lawrence L. No RFS benefit found from adding vibostolimab to pembrolizumab in patients with
high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant
pembrolizumab failed to improve recurrence-free survival and increased toxicity. Cancer 2026;132:e70439.
PMID: 42316576
|
 |
|
